Memscap annual cash and equivalents
2020
2021
2022
2023
2024
2025
Memscap Cash & Equivalents Growth & History (MEMS)
Memscap's cash and equivalents was €4.5M for fiscal 2025.
View full Memscap company overviewMemscap annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €4.5M | €492,000 | +12.41% |
| 2024 | 2024-12-31 | €4.0M | −€838,000 | −17.45% |
| 2023 | 2023-12-31 | €4.8M | €621,000 | +14.86% |
| 2022 | 2022-12-31 | €4.2M | €261,000 | +6.66% |
| 2021 | 2021-12-31 | €3.9M | €967,000 | +32.76% |
| 2020 | 2020-12-31 | €3.0M | — | — |
Memscap quarterly cash and equivalents
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €4.2M | €309,000 | +7.89% |
| Q4 2025 | 2025-12-31 | €4.5M | €492,000 | +12.41% |
| Q2 2025 | 2025-06-30 | €3.9M | — | — |
| Q4 2024 | 2024-12-31 | €4.0M | — | — |
Memscap cash and equivalents trends
Over the last five fiscal years, Memscap's cash and equivalents increased from €3.0M to €4.5M, a change of €1.5M. The latest reported quarter, Q2 2026, shows €4.2M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Memscap source filings ↗Community posts
MEMSCAP more than triples operating profit as sensor sales grow
MEMSCAP ($MEMS) reported unaudited third-quarter 2026 revenue of €3.333 million, up 27.1%, as all three of its markets expanded. Aerospace sales increased 22.8%, medical sales 80.1% and optical communications sales 7.6%. Operating income ro ...
